OncoMatch/Clinical Trials/NCT05183048
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Is NCT05183048 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies [89Zr]Panitumumab Tracer for head and neck squamous cell carcinoma.
Treatment: [89Zr]Panitumumab Tracer — This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Cannot have received: investigational drug
Received an investigational drug within 30 days prior to the first dose of [89Zr]panitumumab.
Cannot have received: surgical resection
Previous HNSCC resection.
Lab requirements
Blood counts
Hemoglobin ≥ 9 gm/dL; White blood cell count ≥ 3000/mm3; Platelet count ≥ 100,000/mm3
Kidney function
Serum creatinine ≤ 1.5 times upper reference range; Creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels; Severe renal disease or anuria [excluded]
Liver function
ALT (SGPT) 7-56 units/liter, AST (SGOT) 5-40 units/liter
Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; White blood cell count ≥ 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range; ALT (SGPT) 7-56 units/liter, AST (SGOT) 5-40 units/liter. Severe renal disease or anuria [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAB · Birmingham, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify